Sylvain Ladoire
Sylvain Ladoire
Faculté de médecine, université de bourgogne
Verified email at
Cited by
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F Ghiringhelli, C Menard, PE Puig, S Ladoire, S Roux, F Martin, E Solary, ...
Cancer immunology, immunotherapy 56, 641-648, 2007
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell–dependent antitumor immunity
J Vincent, G Mignot, F Chalmin, S Ladoire, M Bruchard, A Chevriaux, ...
Cancer research 70 (8), 3052-3061, 2010
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells
F Chalmin, S Ladoire, G Mignot, J Vincent, M Bruchard, JP Remy-Martin, ...
The Journal of clinical investigation 120 (2), 457-471, 2010
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ...
Nature medicine 20 (11), 1301-1309, 2014
Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
E Vacchelli, Y Ma, EE Baracco, A Sistigu, DP Enot, F Pietrocola, H Yang, ...
Science 350 (6263), 972-978, 2015
An immunosurveillance mechanism controls cancer cell ploidy
L Senovilla, I Vitale, I Martins, M Tailler, C Pailleret, M Michaud, L Galluzzi, ...
Science 337 (6102), 1678-1684, 2012
Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory …
S Ladoire, L Arnould, L Apetoh, B Coudert, F Martin, B Chauffert, ...
Clinical cancer research 14 (8), 2413-2420, 2008
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
S Ladoire, F Martin, F Ghiringhelli
Cancer Immunology, Immunotherapy 60, 909-918, 2011
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ...
The Lancet Oncology 22 (7), 931-945, 2021
Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression
F Chalmin, G Mignot, M Bruchard, A Chevriaux, F Végran, A Hichami, ...
Immunity 36 (3), 362-373, 2012
Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria
PE Charles, S Ladoire, S Aho, JP Quenot, JM Doise, S Prin, NO Olsson, ...
BMC infectious diseases 8, 1-8, 2008
Effect of a nurse-implemented sedation protocol on the incidence of ventilator-associated pneumonia
JP Quenot, S Ladoire, F Devoucoux, JM Doise, R Cailliod, N Cunin, ...
Critical care medicine 35 (9), 2031-2036, 2007
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
S Ladoire, G Mignot, S Dabakuyo, L Arnould, L Apetoh, C Rébé, ...
The Journal of pathology 224 (3), 389-400, 2011
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L Apetoh, S Ladoire, G Coukos, F Ghiringhelli
Annals of Oncology 26 (9), 1813-1823, 2015
Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX–bevacizumab drug treatment regimen
E Limagne, R Euvrard, M Thibaudin, C Rébé, V Derangère, A Chevriaux, ...
Cancer research 76 (18), 5241-5252, 2016
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
T Yamazaki, D Hannani, V Poirier-Colame, S Ladoire, C Locher, A Sistigu, ...
Cell Death & Differentiation 21 (1), 69-78, 2014
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
B Guiu, JM Petit, F Bonnetain, S Ladoire, S Guiu, JP Cercueil, D Krausé, ...
Gut 59 (3), 341-347, 2010
Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis
C Guenancia, A Lefebvre, D Cardinale, FY Anthony, S Ladoire, ...
Journal of Clinical Oncology 34 (26), 3157, 2016
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ...
Cancer 121 (15), 2586-2593, 2015
The system can't perform the operation now. Try again later.
Articles 1–20